Ikarian Capital’s AnaptysBio ANAB Stock Holding History

Ikarian Capital’s Portfolio ANAB Stock Details ANAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-161,100	Closed	-$4.93M	–	178
2025 Q3	$4.93M	Buy	+161,100	New	+$3.7M	0.5%	48
2025 Q1	–	Sell	-250,000	Closed	-$3.31M	–	168
2024 Q4	$3.31M	Sell	250,000 -100,000	-29%	-$2.42M	0.45%	62
2024 Q3	$11.7M	Buy	+350,000	New	+$12M	1.63%	12
2021 Q2	–	Sell	-182,100	Closed	-$3.92M	–	216
2021 Q1	$3.92M	Hold	182,100	–	–	0.13%	145
2020 Q4	$3.92M	Buy	+182,100	New	+$4.42M	0.17%	108

Other funds holding ANAB

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Sanofi Paris, France $336M AUM 126.85% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Ikarian Capital's ANAB Position: Q4 2025 in Review

Ikarian Capital sold out of AnaptysBio (ANAB) in Q4 2025, closing a stake of 48,410 shares — an estimated $1.48M sold.

Ikarian Capital first reported a position in ANAB in Q4 2019 and held it in 8 quarters. The position peaked at $2.32M in Q4 2019. 179 funds tracked by Wall St. Rank hold ANAB as of Q4 2025.

Ikarian Capital reported no remaining AnaptysBio position as of Q4 2025 after selling out during the quarter.
Ikarian Capital sold 48,410 AnaptysBio shares in Q4 2025, an estimated $1.48M.
Ikarian Capital first reported a position in AnaptysBio in Q4 2019 and held it in 8 quarters.
Ikarian Capital's AnaptysBio position peaked at $2.32M in Q4 2019.
179 funds tracked by Wall St. Rank held AnaptysBio as of Q4 2025.

Based on Ikarian Capital's 13F filing for Q4 2025, filed 18 Feb 2026.